NCT06111625 2023-11-01
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
Sichuan University
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06075212 2023-10-10
Immune Reconstitution After Allo-HSCT and Blinatumomab
Sichuan University
Unknown
NCT06075238 2023-10-10
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT
Sichuan University
Phase 2 Not yet recruiting
NCT01466179 2017-08-18
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
Phase 2 Completed
NCT01471782 2017-02-08
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH
Phase 1/2 Completed